Topics

GSK Cuts Flu and Pneumonia Vaccines Following Disappointing Data

20:00 EDT 1 May 2019 | BioSpace

GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine. GSK said it remains committed to further research in flu including pursuing other approaches.

Original Article: GSK Cuts Flu and Pneumonia Vaccines Following Disappointing Data

NEXT ARTICLE

More From BioPortfolio on "GSK Cuts Flu and Pneumonia Vaccines Following Disappointing Data"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...